Cannabis Biosciences was formed
and incorporated by Plandaí Biotechnology in 2013 to legally
develop non-psychoactive medicines from live cannabis plant. Using
Plandaí's proprietary processing and extraction technology, the
company intends to commence investigations in conjunction with
independent researchers to develop and validate a full-profile
cannabis extract, one that contains both CBD and the precursor acid
form of THC (THC-A and THC-B) found in live cannabis plant. The
hypothesis is that the resultant extract will have similar,
superior bioavailability of other Phytofare® extracts with the
added benefit of being non-psychoactive. Several third-party
investigations have shown that the precursor acid forms THC-A and
THC-B in live cannabis leaf are inherently non-psychoactive and
that the process of drying and heating the leaf metabolizes these
acid forms into THC, a chemical that triggers the euphoria sought
after by recreational users. The Company's investigations will be
designed to show that the Cannabis Biosciences extraction process,
which will use live leaf and low temperatures to extract the
phyto-chemicals, should leave the acid forms of THC intact,
resulting in a non-psychoactive extract with full medicinal
potential.
Roger Baylis-Duffield, Chief
Executive Officer of Protext, commented, "Where most pharma
companies have chosen to focus on the non-psychoactive CBD
chemical, we believe that this strategy limits the potential
medical benefits. Recent third party studies have demonstrated the
synergistic value of retaining the full chemical profile of
cannabis. Our objective is to validate Cannabis Biosciences
cannabis extracts to be not only full profile but also
non-psychoactive, which will give researchers all of the benefits
of cannabis without the unwanted side effects. The acquisition of
Cannabis Biosciences by Protext properly aligns our pharmaceutical
research under one roof, allowing us to further our cannabis
studies as we strive to create a cannabis extract that can increase
the well-being and potentially improve the lives of so many
people."
We encourage our investors and
shareholders to connect and engage with us through social media.
You can find us on the following;
YouTube: http://bit.ly/ProtextYouTube
Twitter: https://twitter.com/protxtm
Instagram: https://www.instagram.com/protextm/
About Protext Mobility,
Inc.
Protext Mobility, operates two wholly owned subsidiaries; Plandaí
Biotechnology South Africa (SA) and Cannabis Biosciences. The
Company is engaged in the research and clinical testing of
"bioceutical" products -- all natural ingredients formulated for
pharmaceutical applications and processed under pharma-grade
conditions. Through its wholly owned subsidiary Plandaí
Biotechnology SA, the Company has the exclusive worldwide license
to develop pharmaceutical applications and products using the
Phytofare® catechin complex, which was developed by Plandaí
Biotechnology, Inc. Phytofare® is a highly bioavailable extract
produced from live green tea leaves. Our initial product,
Phytofare® Catechin Complex, has been clinically shown to have 10
times greater bioavailability over generic catechin extracts. What
this means is that Phytofare® can deliver a therapeutic level of
catechins, which function as powerful antioxidants, to the system
where they remain active for over 24 hours. Plandaí grows green tea
on its 7,500 acre Senteeko estate in South Africa, where it
produces the proprietary Phytofare® catechin extract in-house,
allowing the Company a continuity of supply as well as quality
control throughout the entire process. Targeted applications for
the Company's products include arthritis, inflammation, anti-viral,
and diabetes-related metabolic syndromes.
Please visit http://www.protextm.co for further
information.
About Cannabis
Biosciences
The Company is actively pursuing government licenses and permits
that will allow it to use its proprietary processing and extraction
technology to commence investigations and produce a full-profile
cannabis extract, one that contains both CBD and the precursor acid
form of THC (THC-A and THC-B) found in live cannabis plant. The
Company's investigations will be designed to show that the Cannabis
Biosciences extraction process, which will use live leaf and low
temperatures to extract the phyto-chemicals, should leave the acid
forms of THC intact, resulting in a non-psychoactive extract with
full medicinal potential and having the heightened bioavailability
of other Phytofare® extracts.
Safe Harbor
Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance or guarantee that such expectations and assumptions
will prove to have been correct. Forward-looking statements are
generally identifiable by the use of words like "may," "will,"
"should," "could," "expect," "anticipate," "estimate," "believe,"
"intend," or "project" or the negative of these words or other
variations on these words or comparable terminology. The reader is
cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous factors and
uncertainties, including but not limited to: adverse economic
conditions, competition, adverse federal, state and local
government regulation, international governmental regulation,
inadequate capital, inability to carry out research, development
and commercialization plans, loss or retirement of key executives
and other specific risks. To the extent that statements in this
press release are not strictly historical, including statements as
to revenue projections, business strategy, outlook, objectives,
future milestones, plans, intentions, goals, future financial
conditions, events conditioned on stockholder or other approval, or
otherwise as to future events, such statements are forward-looking,
and are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made. The company disclaims any
obligation to update information contained in any forward-looking
statement. This press release shall not be deemed a general
solicitation.